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Clinical genome sequencing in an unbiased pediatric cohort
Isabelle Thiffault, PhD1,2,3, Emily Farrow, PhD, CGC1,2,4, Lee Zellmer, MS, CGC1,3,
Courtney Berrios, MSc, CGC1,2, Neil Miller1, Margaret Gibson, MS1, Raymond Caylor, PhD3,
Janda Jenkins, MS, CGC2,4, Deb Faller1, Sarah Soden, MD1,2,4 and Carol Saunders, PhD1,2,3
Purpose: We report for the first time, the use of clinical genome
sequencing (GS) in an unbiased pediatric cohort. We describe the
clinical validation, patient metrics, ordering patterns, results,
reimbursement, and physician retrieval of results for the first
consecutive 80 cases.
Methods: Clinical GS was performed for both inpatients and
outpatients undergoing etiologic evaluations. Results were reported
in the electronic medical record. Evidence of report retrieval by
clinicians and whether interpretation was concordant with
laboratory report was obtained through retrospective chart review.
Results: Twenty definitive diagnoses were made in 19 patients
(24%; n = 80). Except for two partial gene deletions, all diagnostic
variants would have been detectable by our exome methods.
Surprisingly, there was no documentation of communication of
results to the family in the medical record for 17.5% of patients, and

INTRODUCTION
Clinical exome sequencing (ES) has become a widely used tool
for the diagnosis of rare genetic diseases, affording coverage of
the coding region at a fraction of the cost of genome
sequencing (GS). There are advantages and disadvantages to
both methods. Exomes offer higher sequencing depth, albeit
more biased coverage. Genomes have a greater sequencing
and storage cost, but because they do not require enrichment
the laboratory processing time is much shorter. Although
noncoding regions are available with GS, these are largely not
analyzed in the clinical setting. For these reasons, the use of
WGS is generally limited to the research setting. In 2015, our
center launched clinical GS (cGS) following extensive
experience with research-based GS for the molecular
diagnosis of pediatric patients with presumed rare Mendelian
disorders. We introduced a mixed trio next-generation
sequencing (NGS) test, in which GS is performed for the
proband and ES is done for both parents, as available. This
has the benefit of readily identifying de novo variants,
phasing, validation of parentage, and improved variant
interpretation. Here, we report for the first time the use of
clinical GS in a pediatric hospital, including our process,

in 7.5%, physician and laboratory interpretations were discordant.
Average insurance reimbursement was 30.2%, with yield for
commercial payers significantly higher, at 54.1%.
Conclusions: The detection rate of GS is equivalent and
potentially superior to exome sequencing (ES). Reimbursement
rates were variable but overall satisfactory for commercial insurers,
and poor for government entities. In addition, we identify
opportunities for improvement in the communication of results
to families, likely translatable to other tests and other institutions.
Genetics in Medicine (2019) 21:303–310; https://doi.org/10.1038/s41436018-0075-8
Keywords: Genome sequencing; Clinical validation; Nextgeneration sequencing; Diagnostics; Insurance reimbursement

ordering metrics, diagnostic yield, reimbursement, and
clinician interpretation of the report to families.

MATERIALS AND METHODS
Patients and phenotyping

Eighty patients with suspected genetic disorders received cGS
between 13 August 2015 and 24 April 2017 (Suppl. Table 1).
The majority (57) underwent trio sequencing with both
parent samples; 17 were run as parent/child duos, and only 4
as singletons. Two were run as a proband–parent–sibling trio.
The average age of this cohort was 6.9 years. Etiologic testing
was performed for a range of clinical concerns by a variety of
subspecialists. The majority of cGS (47/80 or 59%) was
ordered by geneticists, followed by neurologists (22 or 28%)
and other subspecialists (Table 1) from both inpatient (21)
and outpatient (59) services. Most patients (57/80 or 71%)
were also tested by a genome-wide array methodology (oligoarray comparative genomic hybridization [CGH], singlenucleotide polymorphism [SNP] array, or exon array) and no
diagnostic findings were reported (Suppl. Table 1.) Approval
was obtained from the institutional review board at Children's
Mercy Hospital.
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Table 1 Demographics and ordering metrics of patients who underwent clinical genome sequencing
Characteristics

Total # patients

Total # patients diagnosed

Total # no diagnosis

n = 80

n = 19 (24%)

n = 61 (76%)

Diagnosis rate comparison

5.7

7.3

t = 1.115, p = 0.268

Currently deceased

10 (12.5%)

6/19 (31.5%)

4/61 (6.6%)

x2(1) = 8.29, p = 0.004

Inpatients

21 (26.3%)

11 (58%)

10/61 (16.4%)

x2(1) = 12.889, p < 0.001

57

15

42

Demographics
Patient age at testing

Sequencing mode
Trio (both parents)

Trio vs. other modes:

Singleton

4

1

3

Duo (proband and one parent)

17

3

14

Proband, one parent, sibling

2

0

2

x2(1) = 0.721, p = 0.396

1234567890():,;

Inheritance patterns
De novo

10

Autosomal recessive

5

Autosomal dominant

2

X-linked

1

Mitochondrial

1

Undetermined

1

Average # variants reported/case

6.5

8

Secondary findings
Not requested
Total reported

2
4

3

1

Genetics

47 (59%)

11

36

Neurology

22 (27.5)

3

19

Cardiology

6 (6.5%)

3

3

Immunology

2 (2.5%)

1

1

Subspecialty referral

Genetics vs. other:

Gastroenterology

2 (2.5%)

0

2

Perinatology

1 (1.2%)

1

0

x2(1) = 0.008, p = 0.931

Given the high cost of the cGS, insurance preauthorization
was initiated for all outpatient orders. Following notice of
preauthorization, the parents were consented by a genetic
counselor. If testing was denied, financial assistance or other
options more favorable to the family’s situation were
explored. Inpatients were consented directly by a
genetic counselor with no preauthorization required. GS
was performed on each proband, and ES was completed on
both parents, as available, for segregation analysis
and verification of familial relationships. Alternative
informative family members were also acceptable, dependent on family history. A report revealing the inheritance of
each variant was issued for the proband, however no report
was provided for parents or other relatives. Secondary
findings were reported, if requested. The volume of this
testing is naturally limited at our institution by genetic
counselors’ availability.

library prep following mechanical shearing on the Covaris
LE220. Libraries were analyzed on a TapeStation or Fragment
Analyzer to verify fragment size and distribution before being
sequenced to 90 Gb or greater in 2 × 125 paired reads on the
Illumina HiSeq2500 or 2 × 150 paired reads on a HiSeq4000.
Basecalling was performed and required a minimum of 500 K
raw cluster density with 75% passing filter. In addition, the
percent of reads at or above Q30 should be greater than 80%. If
these quality control (QC) metrics were satisfied, samples were
processed through an alignment and variant detection pipeline
using DRAGEN 2.0.4-2.1.3; although some older samples were
processed using Burrows–Wheeler Aligner 0.7.2 and Genome
Analysis Toolkit 3.2-2. Postpipelining QC included a minimum
of 85% of reads aligning to the human genome and a minimum
of 85 Gb of data obtained after alignment is complete. Variant
annotation and categorization was performed using Rapid
Understanding of Nucleotide variant Effect Software (RUNES
v.3.4.3 – v4.2.4) as previously described.1,2

Sequencing, variant detection, QC, and annotation

Analysis, interpretation, reporting

Genomic DNA from blood (or in three cases, fetal tissue) was
prepared using either Kapa Hyper or Illumina TruSeq HT

For each patient, the phenotype was extracted from the
electronic medical record and recorded using Human

GS testing process
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KPTN

KPTN

TBL1XR1

MTATP6

MYH3

MYH3

ATL1

ACTA1

TCF12

WDR73

COMP

BBS1

ECHS1

ECHS1

BICD2

AARS2

AARS2

MED13L

FBN1£

6

8

9

12

12
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15

24

29

31

31

33

42

42

44

47

47

49

70

D1973G)

AD

(AD)

Met864Lys

het c.5918A>G (p.

De novo

het c.2591T>A, p.

R580W

het c.1738C>T, p.

AR

(AD)

het exons 5-7 del

De novo

N700K)

AR

AR

AD

AR

het c.2100C>G (p.

het exons 6-8 del

A173V)

het c.518C>T (p.

(p.M390R)

homo c.1169T>G

het c.1279_1291del

homo c.888delT

(AD)

De novo

(AD)

het c.1035+5G>A

De novo

G17S)

(AD)

De novo

AR?/AD

het c.49G>A (p.

het p.Arg403Pro

(p.Lys1755del)

het c.5263_5265del

(p.Lys1785del)

het c.5355_5357del

m.8993T>G

MT

(AD)

homoplasmic

De novo

Tyr446Asp)

AR

het c.1336T>G (p.

het c.394+1G>A

het c.714_731dup

(AD)

6

De novo

ACTG1

4

(AD)

De novo

Arg210Cys)

het c.73+1del

ZEB2£

1

Inheritance

pattern

het c.628C>T (p.

Variants

Gene

Marfan syndrome (154700)

features with cardiac defects (616789)

Mental retardation and distinctive facial

8 (614096)

Combined oxidative phosphorylation deficiency

Spinal muscular atrophy (615290)

1 deficiency (616277)

Mitochondrial short-chain enoyl-CoA hydratase

Bardet–Biedl syndrome (209900)

Multiple epiphyseal dysplasia (32400)

Galloway–Mowat spectrum (251300)

Craniosynostosis (615314)

Nemaline myopathy (161800)

Spastic paraplegia (182600)

syndrome (178110)

Arthrogryposis, spondylocarpotarsal synostosis

Leigh syndrome (256000)

Pierpont syndrome (602342)

Intellectual disability (615637)

Baraitser–Winter syndrome 2 (614583)

Mowat–Wilson syndrome (235730)

Diagnosis (OMIM)

Arrhythmia, mitral valve prolapse, myocardial infarction, LQTS, syncope

polymicrogyria

Dysmorphia, cardiomegaly, coarctation of aorta, hydrops fetalis, hypoplastic left heart,

Abnormality of the corpus callosum, dilated cardiomyopathy, lactic acidemia

Akinesia, arthrogryposis multiplex congenita, fetal akinesia sequence

Dystonia, mitochondrial encephalopathy, pallidal degeneration

polydactyly

Abnormal behavior, abnormal nasal base, brachycephaly, deep set eyes, heterotopia, ID,

seizures

Abnormal retinal pigmentation, FTT, focal segmental glomerulosclerosis, HL, microcephaly,

Seizures, GDD, Angelman-like syndrome, coarctation of the aorta, and laryngeal cleft

Cryptorchidism, contractures, microretrognathia, polyhydramnios

Dystonia, hypertonia, FTT, adducted thumb, GDD, spasticity

fusion

Distal arthrogryposis, antecubital pterygium, popliteal pterygium, cleft palate, scoliosis, rib

Abnormal activity of mitochondrial respiratory chain, GDD, lactic acidosis, hypotonia

FTT, hypotonia, GDD, cleft, laryngeal cleft, dysmorphisms, HL, abnormality of the optic nerve

Macrocephaly, intractable epilepsy, ASD, GDD, hypotonia, hypoglycemia, dysmorphia

Microcephaly with brain abnormalities, DD, HL, and foot and hip abnormalities

Microcephaly, Hirschsprung, hypogammaglobulinemia, lymphopenia, fever

Signs and symptoms

Table 2 Diagnostic findings and phenotypes of patients who underwent clinical genome sequencing
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macrocephaly, nystagmus, obesity, epicanthal folds, retrognathia, seizures

AD autosomal dominant, AR autosomal recessive, MT mitochondrial, ID intellectual disability, DD developmental delay, GDD global developmental delay, FTT failure to thrive, HL hearing loss, ASD autism spectrum disorder,
LQTS long QT syndrome
The £ sign distinguishes TRIO or DUO NGS run with siblings vs parental samples

2–3 toe syndactyly, ASD, bulbous nose, hallux valgus, high palate, hypertelorism,

(AD)

Trichorhinophalangeal syndrome (190350)
De novo

Leu263Cysfs*53)

TRPS1
78

het c.787del (p.

ASD, dysphagia, GDD, microcephaly, seizures, status epilepticus, visual impairment
Cornelia de Lange syndrome (300590)
X-linked
R18*)

hemi c.52C>T (p.
SMC1A
72

Hip dislocation, Epileptic encephalopathy, GDD, Heterotopia, Seizures, Spasticity
(607208)
(AD)
F1486V)

Early infantile epileptic encephalopathy 6
De novo
het c.4456T>G (p.
SCN1A
71

Signs and symptoms
Diagnosis (OMIM)
pattern

Inheritance
Variants
Gene

Table 2 continued
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Phenotype Ontology (HPO) terms.3,4 This information was
entered in SSAGA, a clinical correlation tool and database
that maps the phenotypic features of genetic diseases with
candidate genes, allowing for archiving patient phenotypes
and the generation of gene lists for variant filtering.1,2,5,6
Furthermore, Phenomizer was used to generate additional
lists of candidate genes,3 as needed. However, these phenotype
filters were removed to allow for manual nomination of
additional genes relevant to the phenotype. Variants were
identified and filtered to 1% frequency and prioritized by type
using VIKING software, as previously described.1,2,5,6 Intronic
variants more than 20 base pairs from the exon boundary
were not analyzed unless they were previously reported in the
literature as pathogenic, there was a specific gene of interest,
or a partial genotype was uncovered where a second
pathogenic variant would be diagnostic. No copy-number
variant (CNV) caller was used, however, manual inspection of
alignments was performed as needed. Variants in genes
potentially related to the phenotype were interpreted using
the American College of Medical Genetics and Genomics
(ACMG) guidelines.7 Pathogenic, likely pathogenic, and
variants of unknown significance were reported clinically in
addition to pathogenic and likely pathogenic variants in the
ACMG-59 secondary finding gene list,8,9 if requested by the
family. For each patient, it was recorded whether follow-up of
result was documented in the medical record, and whether the
laboratory interpretation concurred with what was conveyed
in providers’ notes.
Clinical validation and QC

Building on a wealth of experience running research GS for
diagnosis of pediatric patients, including rapid genomes in
infants in the neonatal intensive care unit (NICU),2,5,6 we
sought to validate GS clinically. A total of 179 GS samples had
been run on a research basis, including affected children and
their family members. In a highly selected population such as
infants in the NICU, the diagnostic rate was as high as 57%,
indicating high clinical utility.5 Diagnostic variants in these
cases were confirmed by clinical Sanger sequencing with no
discrepancies. For clinical validation, a control sample,
NA12878, was run four times on two different instruments
and compared with the GetRM dataset supplied by the
Centers for Disease Control and Prevention. In addition,
multiple replicates of two other controls, NA12753 and
NA07019, were run and compared with data generated from
the Omni5 SNP chip by the HapMap project and, a research
sample, UDT_173, was run twice and subjected to the same
comparison. Sensitivity and specificity were determined by
defining true positives as variants present in both GS and SNP
chip; false negatives were called if a variant was present in the
SNP chip data alone; false positives were defined as variants
called only by GS. True negatives were defined as negative in
both NGS and SNP chip data. In addition, alignment statistics
were provided. This analysis was extended to compare single
read pools as well as a hybrid, single read, and paired end
pool, with no differences observed. The following was
Volume 21 | Number 2 | February 2019 | GENETICS in MEDICINE
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determined based on averaging the calculations for individual
runs: sensitivity, 98.7%; specificity, 99.2%; accuracy, 98.4%;
precision, 99.8%. Rapid versus nonrapid: exomes and targeted
panel runs were compared in v2 rapid chemistry versus v4
high output chemistry. NA12878 genomes were compared in
v4 high output versus v1 ultra rapid chemistry; results were
essentially identical. In addition, alignment rates as well as
sensitivity/specificity were compared between rapid runs and
nonrapid on the HiSeq2500 and found to be equivalent.
The average depth of coverage for coding region bases was
37.71×, with 98.2% of bases covered at 10× and 88.5% covered
at 20× (Suppl. Table 2). Median exonic coverage was 38.1×.
Across the entire genome, average coverage was 40.7×, with
97.1% of all bases covered at 10× and 91.3% of bases covered
at 20×. Mean number of variants was 4.81 M with 4.13 M
SNV and 676,043 K small indel calls per patient. Of these, on
average, 457,716 had a frequency less than 1% and 26,892
were coding. CNVs were not evaluated systematically by a
software tool, but alignments were examined manually as
needed. Array-CGH or SNP array was performed separately,
as requested.

RESULTS
Diagnostic yield

A total of 20 definitive diagnoses were made in 19 patients,
yielding a diagnostic rate of 24% (n = 80) (Table 2). Of these,
1 patient had 2 diagnoses. In addition, a number of
patients have potentially positive results requiring further
follow-up with functional or other studies (Suppl. Table 1).
Two cases had definitive diagnoses but had additional
symptoms not explained by the diagnosis: for example, case
1 had a diagnosis of Mowat–Wilson syndrome, with
additional findings including hypogammaglobulinemia, lymphopenia, and fever; and case 70 had an FBN1 variant
consistent with Marfan syndrome but had an undiagnosed
arrhythmia as well. The average number of variants reported
per patient was 7.6 (6.5 for diagnostic group and 8 for
nondiagnostic group; Table 1) Not surprisingly, patients who
underwent trio sequencing had a higher rate of diagnoses (15/
57, 26%) than other modalities (4/23, 17%; Table 1). Of the
diagnostic group, 6 of 19 patients (32%) were deceased,
including 3 fetal demises and one still birth, whereas only 4 of
61 in the undiagnosed group (7%) were deceased (P = 0.004;
significant). The odds of receiving a diagnosis were 7.01 (95%
confidence interval [CI] = 2.25, 21.82; p = 0.001) times higher
in those ordered in an inpatient setting (52%) than those
completed in outpatient settings (14%). However, there was
no statistically significant difference in rate of diagnosis
between testing ordered by genetics as compared with other
specialties, nor was there a difference by age at the time of
testing. Although every potential inheritance pattern was
observed in this study, the most common mode was de novo
(10/20 or 50%; Tables 1, 2). In one case, the inheritance
pattern was unclear because the patient was compound
heterozygous for two predicted loss of function variants in
MYH3, a gene associated with autosomal dominant disease.
GENETICS in MEDICINE | Volume 21 | Number 2 | February 2019

The average turnaround time was 72.5 days; however, results
were expedited in critical cases upon request.
Secondary findings

During the informed consent process, 73/80 (91.2%) families
opted in to receive secondary findings. Secondary findings
were reported in four cases, with variants in APOB, PMS2,
RYR1, and TNNT2 (Suppl. Table 1).
Comparing ES vs. GS

To compare ES with GS, diagnostic variants from cGS were
examined in a summary coverage report for an exome
validation dataset of 814 samples. In all cases except two, the
diagnostic genotype detected by GS would have been detected
by ES given sufficient coverage of the nucleotide (Suppl.
Table 2); the exceptions being two partial gene deletions.
These cases illustrate the superiority of GS for the detection of
deletions (Suppl. Data: Illustrative cases).
Communication of results

Genomic reports are complex, and the communication of
results to families is challenging. The amount of information
in genomic reports may be difficult to prioritize, with an
average of eight variants reported per patient in this cohort.
Providers may have limited knowledge of variant interpretation categories as well as evidence-based guidelines used for
variant classification. In addition, families may have limited
understanding of the information conveyed. Given the
importance of cGS results and their potential impact for
clinical management, we sought documentation in all 80 cases
of communication of results by the provider to the family in
the electronic medical record (EMR) and whether this was in
agreement with what was reported by the laboratory.
Surprisingly, for 14 of 80 (17.5%) patients, we did not find
documentation of communication of the results to the family
(Suppl. Table 1). Of the cases not disclosed to families, most
were nondiagnostic; however, case 24 had a diagnostic result
as well as a reportable secondary finding. Seven of the 14 cases
(50%) with no documentation were ordered as inpatients,
despite representing only 26% of the overall cohort. Indeed,
documentation of results communication was not found for
33% of inpatients compared with 12% of outpatients (odds
ratio [OR] = 3.71, 95% CI = 1.12, 12.36; p = 0.032). This
failure to document return of results in the EMR raises
concern that results were not disclosed to families; of note in
three cases results were not even viewed by treating providers.
The odds of GS cases referred by Genetics not having
documentation of result communication were 0.136 times
lower (95% CI = 0.03, 0.54; p = 0.005) than that of the odds
in cases referred by other subspecialties.
Of the remaining 66 cases with documented results
disclosure, 6 (9%) were found to be discordant between the
laboratory report and clinicians’ interpretations recorded in
the EMR (Suppl. Table 3). From the laboratory perspective,
five of these cases were considered nondiagnostic and
reported with variants of uncertain significance (VUSs). In
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case 23, the physician mistakenly interpreted two VUS in two
different autosomal recessive genes with similar names as
being diagnostic, citing “two mutations in ATP13, consistent
with DYT12.” In case 22, the lab reported a nondiagnostic
genotype with compound heterozygous VUSs in TCIRG1,
interpreted by the clinician as being diagnostic for autosomal
recessive osteopetrosis, a transplantable condition. The
patient was placed on the transplant list but has no matched
donor and currently shows minimal biochemical evidence of
disease. In case 26, a maternally inherited VUS in TSC2,
c.1440_1441insGAG, also present in an affected sibling, was
communicated as being a VUS by a clinical geneticist
following examination specifically looking for stigmata of
tuberous sclerosis complex (TSC). Although both siblings had
imaging showing renal angiomyolipomas, in the absence of
other findings (including normal brain magnetic resonance
image [MRI]) there was insufficient criteria to clinically
diagnose TSC. However, follow-up clinic notes in other
subspecialties, including neurology and nephrology, recorded
“genetically confirmed or likely TSC” and patient was
transitioned to TSC clinic. The fourth discrepancy was in
case 44, a stillborn female fetus with prenatal onset of
arthrogryposis (reported as patient 4) (ref. 10) and a de novo
BICD2 variant reported as pathogenic and diagnostic. Because
BICD2 variants had not been associated with prenatal onset
disease, the clinical team hedged on calling it diagnostic,
emphasizing a potential role of VUSs in a second gene,
AGRN. Since the time of reporting, at least four isolated
patients with arthrogryposis multiplex congenita and hypotonia have been reported with de novo BICD2 missense
variants.11,12 In case 45, the ordering provider concurred that
the study was inconclusive, however, subsequent notes from a
provider in the same clinic called the variant pathogenic and
diagnostic. Finally, in case 55, while the cGS results were
reviewed in the genetics follow-up note as being nondiagnostic VUSs, array-CGH was recommended and reported as a
CNV, which was interpreted in a different clinic as a “known
diagnosis.”
Cost and reimbursement

For this cohort, we obtained insurance preauthorization for
56 patients, and reimbursement data was available for 38
patients billed for GS. Cumulatively, the average total
reimbursement was 30.2%, however government payers
reimbursed at a lower rate overall than commercial payers,
with the 17 claims filed to commercial insurance, yielding
54.1% reimbursement versus only 13.1% for the 21 claims
filed to government payers. Some of this is explained by the
capitation of one of the largest government payers in this area;
however, even when taking this into consideration the
reimbursement rate is lower than commercial payers. Another
explanation is that commercial payers are more likely to
require authorization while government payers often respond
“Authorization not required.” Testing performed when
authorization is neither required nor obtained is more likely
to be denied after the test is performed. In addition, we note a
308
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potential trend of rejecting cGS in favor of NGS-based panels
or ES. Indeed, GS is considered “experimental” and is not
covered by one of our largest commercial payers.

DISCUSSION
Here we describe the first validation of cGS, and present the
results, reimbursement rate, and follow-up from the first 80
cases reported clinically at a pediatric hospital. Our findings
indicate that cGS is equivalent and potentially superior to ES,
with a diagnostic rate of 24% in this cohort. As with any
study, detection rates for both ES and GS range from 25 to
57% varying with the inclusion criteria.1,5,6,13–16 Unlike other
studies of GS with highly selected patients based on degree
of suspicion of a genetic disease, high rates of consanguinity,16–18 insistence on the availability of parent samples for
trio analysis,16 or other inclusion criteria that could positively
influence the diagnostic rate, this group is an unbiased cohort
based on normal ordering patterns from a range of
subspecialists in a pediatric setting. The average age of our
patients was 6.9, and only 2 of 19 (10.5%) patients with a
diagnosis were from consanguineous parents. In addition, this
analysis was done using a conservative application of the
ACMG guidelines for variant interpretation, unlike some
studies that predated such guidelines.1,13 This study confirms
the value of including parental samples in the analysis, as 95%
of our diagnoses were patients with at least one parental
sample run, and 79% were full trios. In addition, as other
studies have reported,5,19 we confirm that patients in the
diagnostic group have a significantly higher death rate (32%
diagnosed vs. 7% undiagnosed; p = 0.025).
Negative results in the ~50–75% of patients undergoing ES
or GS may be due to several factors, including the limited
ability to accurately interpret variants, particularly in
noncoding regions, current technical limitations, atypical
patient phenotypes at the time of testing, and nongenetic or
complex disease etiologies. In addition, there is still a large
number of genes with limited or no known association with
human diseases, with 20 or more new OMIM associations
every month. However, even in well-characterized genes,
variant interpretation remains challenging, with most
interpreted as VUS. This highlights a tremendous need for
additional studies to elucidate variant pathogenicity and
further vet genes of unknown function. Although noncoding
variants such as deep intronic variants affecting splicing or
regulatory regions are detectable by GS, such variants, which
far outnumber those in the coding regions, are not part of our
current analysis protocol unless previously reported in the
literature as pathogenic. The effects of such variants require
functional characterization, and such investigation is outside
the scope of clinical testing. However, patient variant files are
stored for potential reanalysis when knowledge of this data
matures. Additional explanations for undiagnosed patients
include technical limitations associated with short read
sequencing, which preclude the detection of triplet repeats,
methylation defects, variants in homologous regions, and, in
the absence of special software, many copy-number variants.
Volume 21 | Number 2 | February 2019 | GENETICS in MEDICINE
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While ordering physicians may submit a periodic reanalysis of
cGS to interrogate newly discovered genes with human
disease associations and updated variant annotation, automatic reanalysis is not performed as part of our procedure nor
was it done for this study.
The advantages of cGS are many, both on the laboratory
and analysis side. The workflow for laboratory
staff is less labor intensive because there is no enrichment
step. Other positive factors are evenness and overall less bias
in coverage as compared with ES. Importantly, increased
coverage results in a decrease in supplemental Sanger fill-ins
for areas missed by ES, increased resolution of absence of
heterozygosity for potential uniparental disomy, and exonic
deletions, whole gene or multigene, are potentially detectable.
Although a pipeline for detection of copy-number variants
was not used, two partial gene deletions were found by
manual inspection of alignments, leading to a faster diagnosis
for critical patients in two cases (Suppl. data: Illustrative
cases). Certainly the presence of a single VUS may have
triggered additional testing such as exon-level arrayCGH; however this would depend on the degree of interest
in the candidate gene based on phenotypic fit, follow-up of
the clinician, and regardless, would add to the time to
report the final result. For both ES and GS, short read
technology poses a challenge for the detection of variants
complicated by pseudogenes or other homologous regions,
and repetitive regions. However, advances in technology, both
in software development and laboratory solutions, are
beginning to offer feasible solutions for reliable CNV
detection from GS and ES.
Costs and reimbursement

Despite the advantages, one cannot ignore the current
expense of GS compared with ES, which is at least five times
higher. Storage costs must also be considered, and GS
generates 10 times the data of an exome.
Reimbursement for genetic testing remains challenging, and
advocating for fair payment for these services is needed.
Indeed, commercial payers with negotiated rates paid well;
however, reimbursement by government payers was much
lower and had a higher denial rate. Efforts to educate such
entities on the importance and potential cost-effectiveness of
this testing are needed. In a self-contained institution it is
potentially worthwhile to offer genomic services regardless of
reimbursement in certain patients if it lowers overall costs of
hospitalization or other testing. However, this requires further
study.
Utilization of genomic results

We have identified a significant problem of undisclosed or
undocumented genomic results, unlikely limited to GS or our
institution. This is concerning for any laboratory test, but is
especially problematic for cGS/ES, the results of which often
change the management of patients1,5,6,16,19 and is extremely
costly to perform. It is certainly possible that verbal
communication occurred and was not documented in the
GENETICS in MEDICINE | Volume 21 | Number 2 | February 2019
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EMR; however in three cases there was a failure to view the
cGS results by the ordering provider. The finding that 50% of
the patients whose cGS was ordered during a hospitalization
potentially did not receive results, indicates continuity of care
following discharge is potentially problematic and provides an
opportunity for intervention. While lab stewardship was
found to be a problem in many subspecialties, it was relatively
minimal in genetics, suggesting the involvement of a
genetic counselor, for many reasons, is ideal. Of those results
where communication was documented in the EMR, there
was discordant interpretation between what the lab reported
and what the provider communicated to the patient in six
cases. The apparent reasons for this varied, but in half the
cases was related to the patient phenotype, whether upgrading
a VUS because it was felt to fit the phenotype, or deemphasizing a variant because the phenotype was atypical.
Variant interpretation guidelines do take phenotype into
account but this is not considered strong criteria. The
majority of cases with discordant interpretations between
the laboratory and provider (5/6) were considered nondiagnostic by the laboratory, suggesting physicians may upgrade
variants without the level of evidence required by the
laboratory or may not understand the variant classification
system used. Education of clinicians on methods for variant
classification may be helpful. Interestingly, there was
discordance in interpretations between different providers in
three cases, which may reflect differing levels of genetics
education. What the families are told by providers and what
they understand adds an additional layer of complexity. This
dataset is small but highlights a need for additional studies to
identify the problem of failure to retrieve, disclose, or
document genomic testing results, as well as variant
reinterpretation by clinicians.
The increasing number of atypical or novel presentations
catalogued as a broadened phenotypic spectrum for any
particular genetic condition formerly ordered as a single-gene
or panel-based test challenges the previous model of
using serial genetic testing dictated by phenotype. With
notable exceptions, most genetic conditions have enough
heterogeneity and/or variability to warrant broad screening
such as ES or GS. Many studies offer comparisons between
“conventional” and genomic testing.1,5,6,13,16,19–23 At our
institution, genomic medicine, including GS, has been used
as conventional testing for several years, which benefits
our patients by shortening their course to diagnosis and
potential treatment.1,2,5,6 Here we show GS is equivalent or
perhaps superior to ES from both the laboratory and
diagnostic perspective. However, in all cases but two, where
deletions where identified, ES would yield the same
usable information for current clinical analysis. Therefore,
in the absence of a low-cost high-throughput instrument,
the cost of GS is currently difficult to justify, given the
availability of ES. However, as the cost of sequencing
decreases and the ability to interpret noncoding variants
improves, an increasing diagnostic advantage of GS over ES
will be realized.
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